

## HELIX BIOMEDIX INC. Files SEC form 8-K, Other Events

Mar 16, 2004 - Washington, DC

U.S. SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

---

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): March 9, 2004  
HELIX BIOMEDIX, INC.

---

(Exact Name of Registrant as Specified in Charter)  
Commission file number: 033-20897-D  
DELAWARE 91-2099117

---

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)  
22122 20TH AVENUE S.E., SUITE 148, BOTHELL, WA 98021

---

(Address of principal executive offices) (Zip Code)  
(425) 402-8400

---

Registrant's telephone number, including area code  
Helix BioMedix, Inc.

---

### Item 5. Other Events and Regulation FD Disclosure

On March 9, 2004, Helix BioMedix, Inc. ("Helix") entered into an extension of its research use license agreement with E.I. du Pont de Nemours and Company ("DuPont"). Under terms of the agreement, Helix granted a limited license of specified peptides to DuPont for use in certain internal research activities and to develop a process of manufacturing the specified peptides. Under terms of the extension DuPont has the right to continue to conduct research through October 1, 2005 to determine the feasibility of using the Helix peptides to develop a commercial product. Depending upon the outcome of the research, the companies agreed to negotiate in good faith to enter into a commercial license for use of the Helix peptides.

### SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Helix BioMedix Inc. (Registrant)

Date: March 9, 2004      /s/ R. Stephen Beatty

-----

-----

R. Stephen Beatty  
President and Chief Executive Officer